Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy

Published:December 31, 2016DOI:



      Altered body composition is frequently observed in Crohn’s disease (CD) patients.


      To investigate the nutritional status, and the effect of different therapeutic regimes in adult CD patients.


      Fat free mass (FFM) and BIA-derived phase angle (PhA) were assessed in 45 CD patients, 22 on conventional therapy (CT) and 23 on maintenance therapy with infliximab (MT). Nutritional status was also assessed in 12 CD patients before and following the induction protocol with infliximab. BIA data of CD patients were compared with those of 20 healthy asymptomatic volunteers. In CD patients C Reactive Protein (CRP) and albuminaemia dosage were obtained.


      The mean values of PhA and of FFM were significantly lower in CT patients when compared with control group and MT patients. Following infliximab treatment FFM increased, although not significantly, while mean phase angle value significantly increased from 4.6 ± 0.3 to 6.2 ± 0.4 (p < 0.05). CRP was significantly lower in MT patients compared to that in CT patients.


      CD patients on conventional therapy showed a lower FFM and a lower mean phase angle score compared to those on infliximab therapy. Following infliximab treatment the mean phase angle score normalized. PhA is a reliable nutritional indicator in IBD patients and could be considered as an additional tool for assessing response to treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mijac D.D.
        • Janković G.L.
        • Jorga J.
        • et al.
        Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment.
        European Journal of Internal Medicine. 2010; 21: 315-319
        • Gassull M.A.
        Nutrition and inflammatory bowel disease: its relation to pathophysiology, outcome and therapy.
        Digestive Diseases. 2003; 21: 220-227
        • Goh J.
        • O’Morain C.A.
        Review article: nutrition and adult inflammatory bowel disease.
        Alimentary Pharmacology and Therapeutics. 2003; 17: 307-320
        • Capristo E.
        • Addolorato G.
        • Mingrone G.
        • et al.
        Effect of disease localization on the anthropometric and metabolic features of Crohn’s disease.
        The American Journal of Gastroenterology. 1998; 93: 2411-2419
        • Alastair F.
        • Emma G.
        • Emma P.
        Nutrition in inflammatory bowel disease.
        JPEN. Journal of Parenteral and Enteral Nutrition. 2011; 35: 571-580
        • Bryant R.
        • Trott
        • Bartholomeusz F.
        • et al.
        Systematic review: body composition in adults with inflammatory bowel disease.
        Alimentary Pharmacology and Therapeutics. 2013; 38: 213-225
        • Lukaski H.C.
        • Johnson P.E.
        • Bolonchuk W.W.
        • et al.
        Assessment of fat-free mass using bioelectrical impedance measurements of the human body.
        The American Journal of Clinical Nutrition. 1985; 41: 810-817
        • Norman K.
        • Stobaus N.
        • Pirlich M.
        • et al.
        Bioelectrical phase angle and impedance vector analysis—clinical relevance and applicability of impedance parameters.
        Clinical Nutrition. 2012; 31: 854-861
        • Norman K.
        • Kirchner H.
        • Lochs H.
        • et al.
        Malnutrition affects quality of life in gastroenterology patients.
        World Journal of Gastroenterology. 2006; 12: 3380-3385
        • Gupta D.
        • Lis C.G.
        • Dahlk S.L.
        • et al.
        Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer.
        The British Journal of Nutrition. 2004; 92: 957-962
        • Werkstetter K.J.
        • Ullrich J.
        • Schatz S.B.
        • et al.
        Lean body mass, physical activity and quality of life in paediatric patients with inflammatory bowel disease and in healthy controls.
        Journal of Crohn’s and Colitis. 2012; 6: 665-673
        • Targan S.R.
        • Hanauer S.B.
        • van Deventer S.J.
        • et al.
        A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn disease cA2 Study Group.
        The New England Journal of Medicine. 1997; 337: 1029-1035
        • Hanauer S.B.
        • Feagan B.G.
        • Lichtenstein G.R.
        • et al.
        Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial.
        Lancet. 2002; 359: 1541-1549
        • Travis S.
        • Van Assche G.
        • Dignass A.
        • et al.
        On the second ECCO Consensus on Crohn’s disease.
        Journal of Crohn’s and Colitis. 2010; 4: 1-6
        • Best W.R.
        • Becktel J.M.
        • Singleton J.W.
        • et al.
        Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study.
        Gastroenterology. 1976; 70: 439-444
        • World Health Organization (WHO)
        Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee.
        World Health Organization Technical Report Series. 1995; 854: 1-452
        • Thayu M.
        • Denson L.A.
        • Shults J.
        • et al.
        Determinants of changes in linear growth and body composition in incident pediatric Crohn’s disease.
        Gastroenterology. 2010; 139: 430-438
        • Vespasiani Gentilucci U.
        • Caviglia R.
        • Picardi A.
        • et al.
        Infliximab reverses growth hormone resistance associated with inflammatory bowel disease.
        Alimentary Pharmacology and Therapeutics. 2005; 21: 1063-1071
        • Merola E.
        • Mattioli E.
        • Minimo C.
        • et al.
        Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21 waf-1, p27, and PCNA in Barrett’s esophagus.
        Journal of Cellular Physiology. 2006; 207: 512-519
        • Valentini L.
        • Schaper L.
        • Buning C.
        • et al.
        Malnutrition and impaired muscle strength in patients with Crohn’s disease and ulcerative colitis in remission.
        Nutrition. 2008; 24: 694-702
        • Lochs H.
        • Dejong C.
        • Hammarqvist F.
        • et al.
        ESPEN guidelines on enteral nutrition: gastroenterology.
        Clinical Nutrition. 2006; 25: 260-274
        • Wiese D.
        • Lashner B.
        • Seidner D.
        Measurement of nutrition status in Crohn’s disease patients receiving infliximab therapy.
        Nutrition in Clinical Practice. 2008; 23: 551-556
        • Nakahigashi M.
        • Yamamoto T.
        Increases in body mass index during infliximab therapy in patients with Crohn’s disease: an open label prospective study.
        Cytochine. 2011; 56: 531-535